Current diabetes drugs: Lessons learned and implications for next-generation therapeutics

Diabetes mellitus represents one of the most significant and costly health burdens worldwide. Despite major therapeutic advances over the past three decades, substantial unmet needs remain in glycemic durability, β-cell preservation, weight management, metabolic inflammation, lipotoxicity, and long-term cardiovascular and renal protection. This review synthesizes the molecular basis of diabetes pathogenesis, summarizes therapeutic evolution across drug classes, and highlights emerging technologies accelerating target discovery and translational development. Particular emphasis is placed on incretin-based multi-agonists, metabolic-inflammation modulators, β-cell therapeutics, and machine-learning–enabled discovery platforms. More importantly, a new "metabolism-immune-neuroendocrine" integrated therapy framework is proposed for future diabetes intervention. Together, these innovations are reshaping the landscape for the next generation of diabetes therapeutics.